COVID-19 is a respiratory infectious disease caused by the SARS-CoV-2 coronovirus. Symptoms of COVID-19 can include fever, cough, shortness of breath, chills, headache, muscle pain, sore throat, fatigue, congestion, or loss of taste or smell. Other less common symptoms include gastrointestinal symptoms like nausea, vomiting, or diarrhea.
More than 90% of positive COVID-19 cases do not require hospitalization, but infected patients are at a significant risk of health decline and transmission to others. Even with the growing availability of effective vaccines, a large portion of the world’s population is expected to remain unvaccinated and at risk of COVID-19 infections. Thus, there remains a significant need for an accessible, effective and safe treatment option for non-hospitalized patients infected with COVID-19.
AR-711 and AR-701 are highly neutralizing monoclonal antibodies against SARS-COV-2 virus and its variants. These mAbs are discovered from screening the B-cells of convalescent COVID-19 patients.